

SAÚDE

EM DESTAQUE

V d A E X P E R T I S E



11 a 15 de outubro de 2021

LEGISLAÇÃO

NACIONAL

[Declaração de Retificação n.º 33/2021](#)

Presidência do Conselho de Ministros – Secretaria-Geral

Retifica o [Decreto-Lei n.º 78-A/2021](#), de 29 de setembro, que altera as medidas excecionais e temporárias relativas à pandemia da doença COVID-19

EUROPEIA

[Retificação do Regulamento \(UE\) 2021/1099 da Comissão, de 5 de julho de 2021, que altera os anexos II e III do Regulamento \(CE\) n.º 1223/2009 do Parlamento Europeu e do Conselho relativo aos produtos cosméticos \(JO L 238 de 6.7.2021 \)](#)

[Alterações aprovadas pelo Parlamento Europeu, em 13 de novembro de 2020, sobre a proposta de regulamento do Parlamento Europeu e do Conselho relativo à criação de um programa de ação da União no domínio da saúde para o período 2021-2027 e que revoga o Regulamento \(UE\) n.º 282/2014 \(«Programa UE pela Saúde»\) \(COM\(2020\)0405 – C9-0152/2020 – 2020/0102\(COD\)\)](#)

REGULAÇÃO

ECONOMIA E TRANSIÇÃO DIGITAL, FINANÇAS E SAÚDE

[Regulamento n.º 915/2021](#)

Ordem dos Médicos

Proposta de Regulamento Constituição das Equipas Médicas nos Serviços de Urgência

[Despacho n.º 10049/2021](#)

Saúde - Gabinete do Secretário de Estado da Saúde

Aprova o modelo de guia de tratamento de receita médica hospitalar desmaterializada

[Despacho n.º 9936/2021](#)

Administração Interna e Saúde - Gabinetes da Secretária de Estado da Administração Interna e do Secretário de Estado Adjunto e da Saúde

Determina os subsídios a atribuir pelo Instituto Nacional de Emergência Médica, I. P., para os postos de emergência médica (PEM) e postos reserva (PR)

[Despacho n.º 9860/2021](#)

Saúde - Gabinete da Ministra

Designa para o cargo de diretor executivo do Agrupamento de Centros de Saúde do Pinhal Interior Norte, pelo período de três anos, o licenciado Victor Hugo Ferreira Bernardo

INFARMED

[Publicação para efeitos do artigo 15º-A do Decreto-Lei n.º 176/2006, de 30 de Agosto - pedidos de autorização de introdução no mercado de medicamentos genéricos.](#)

[EMA inicia avaliação de medicamento para a COVID-19](#)

[Circular Informativa Conjunta 013/2021/INFARMED/ACSS/SPMS](#) | Normas técnicas e especificações e requisitos técnicos dos sistemas informáticos de prescrição e dispensa de medicamentos a utentes em regime de ambulatório hospitalar pelos serviços farmacêuticos hospitalares do SNS

[Infarmed Newsletter n.º 194](#)

[Comissão Europeia convida representantes da sociedade civil para participarem no Conselho de Administração e em Comitês da EMA](#)

[Circular Informativa 110/CD/100.20.200](#) | Atualização da lista de medicamentos cuja exportação é temporariamente suspensa

[Presidente do Infarmed eleito Presidente da Heads of Agencies Group \(HAG\)](#)

DGS

[Norma nº 019/2020 de 26/10/2020 atualizada a 13/10/2021](#) | COVID-19: Estratégia Nacional de Testes para SARS-CoV-2

[Orientação nº 038/2020 de 17/12/2020 atualizada a 12/10/2021](#) | COVID-19: Acompanhantes e Visitas nas Unidades Hospitalares

[Norma nº 021/2020 de 23/12/2020 atualizada a 10/10/2021](#) | Campanha de Vacinação contra a COVID-19: Vacina COMIRNATY®

[Norma nº 002/2021 de 30/01/2021 atualizada a 08/10/2021](#) | Campanha de Vacinação Contra a COVID-19

REGULAÇÃO

EMA

Medicinal Products for Human Use | News and press releases: [First-in-class medicine to treat aggressive form of breast cancer](#)

Medicinal Products for Human Use | News and press releases: [Meeting highlights from the Committee for Medicinal Products for Human Use \(CHMP\) 11-14 October 2021](#)

Medicinal Products for Human Use | Regulatory and procedural guideline: [Qualification opinion on IMI PREFER](#)

Medicinal Products for Human Use | Regulatory and procedural guideline: [HMPC rules of procedure \(updated\)](#)

Medicinal Products for Human Use | Report: [Medicinal products for human use: monthly figures - September 2021](#)

Medicinal Products for Human Use | Regulatory and procedural guideline: [ICH guideline E8 \(R1\) on general considerations for clinical studies](#)

Medicinal Products for Human Use | Other: [Records of data processing activity for Clinical data publication website](#)

Medicinal Products for Human Use | News and press releases: [EMA starts rolling review of Evusheld \(tixagevimab and cilgavimab\)](#)

Medicinal Products for Human Use | Other: [Tailored Scientific advice to support step-by-step development of new biosimilars \(updated\)](#)

Medicinal Products for Human Use | Report: [Tailored Scientific Advice for biosimilar development: report on the experience from the pilot \(2017-2020\)](#)

Medicinal Products for Human Use | Other: [Principles for Sponsor organisation modelling for CTIS](#)

Medicinal Products for Human Use | Regulatory and procedural guideline: [COMP rules of procedure \(updated\)](#)

Medicinal Products for Human Use | Other: [CHMP rules of procedure \(updated\)](#)

Medicinal Products for Human Use | Regulatory and procedural guideline: [CAT rules of procedure \(updated\)](#)

Medicinal Products for Human Use | News and press releases: [EMA ends rolling review of CVnCoV COVID-19 vaccine following withdrawal by CureVac AG](#)

Medicinal Products for Human Use | Other: [Article 57 product data \(updated\)](#)

Medicinal Products for Human Use | Agenda: [Agenda - PDCO agenda of the 12-15 October 2021 meeting](#)

Medicinal Products for Human Use | Other: [Letter of support for International Niemann-Pick Disease Registry \(INPDR\)](#)

Medicinal Products for Human Use | Agenda: [Agenda - CHMP agenda of the 11-14 October 2021 meeting](#)

EMA

Medicinal Products for Human Use | Other: [Step-by-step guide : Assess an annual safety report – CTIS Training Programme – Module 20](#)

Medicinal Products for Human Use | Other: [Instructor's guide: Assess an annual safety report – CTIS Training Programme – Module 20](#)

Medicinal Products for Human Use | Other: [FAQs: Assess an annual safety report – CTIS Training Programme – Module 20](#)

Medicinal Products for Human Use | Other: [Crossword puzzle: How to assess an annual safety report – CTIS Training Programme – Module 20](#)

Medicinal Products for Human Use | News and press releases: [EMA receives application for marketing authorisation for Ronapreve \(casirivimab / imdevimab\) for treatment and prevention of COVID-19](#)

Medicinal Products for Human Use | Other: [Clinical Trial Information System \(CTIS\) – Sponsor user personas \(updated\)](#)

Medicinal Products for Human Use | Agenda: [Agenda – PDCO agenda of the 22–25 June 2021 meeting \(updated\)](#)

Medicinal Products for Human Use | Regulatory and procedural guideline: [Member states contact points for translations review \(updated\)](#)

Medicinal Products for Human Use | Agenda: [Agenda – CAT agenda of the 6–8 October 2021 meeting](#)

Medicinal Products for Human Use | Template or form: [Plasma master file timetable: 60–day – Period 2021–2024 \(updated\)](#)

Medicinal Products for Human Use | Template or form: [Plasma master file timetable: 30–day – Period 2021–2024 \(updated\)](#)

Medicinal Products for Human Use | Template or form: [Plasma master file timetable: 90–day – Period 2021–2024 \(updated\)](#)

Medicinal Products for Human Use | Other: [European Union Clinical Trials Information System CTIS: Go-live planning – Summary of key areas in preparation of the operation of CTIS](#)

Medicinal Products for Human Use | News and press releases: [Highlights of Management Board – October 2021 meeting](#)

Medicinal Products for Veterinary Use | Regulatory and procedural guideline: [CVMP rules of procedure \(updated\)](#)

Medicinal Products for Veterinary Use | Minutes: [Minutes of the CVMP meeting of 7–9 September 2021](#)

Medicinal Products for Veterinary Use | News and press releases: [Meeting highlights from the Committee for Medicinal Products for Veterinary Use \(CVMP\) 5–7 October 2021](#)

Medicinal Products for Veterinary Use | Agenda: [Agenda – Info day for micro, small and medium-sized enterprises \(SMEs\): EMA support for SMEs under the new Veterinary Medicinal Products Regulation \(updated\)](#)

Report: [Final programming document 2021–2023 \(updated\)](#)

Other: [Decision of the Management Board on amending budget No. 01, amending appropriations in budget 2021](#)

EMA

Report: [Outcome of written procedures finalised during the period from 26 May 2021 to 13 September 2021](#)

Report: [European Medicines Agency mid-year report 2021 \(January-June 2021\)](#)

Other: [Revised rules of procedure of the Management Board \(updated\)](#)

HMA

[NEW - 12-14 October CMDh Agenda](#)

**COMISSÃO
EUROPEIA**

[EU Health Policy Platform webinar – EU4Health 2021 work programme Information Session second wave of calls for action grants \(28 October 2021, 9:45-13:30 CET\)](#)

[Second wave of the EU4Health calls for project grants now published](#)

[Independent Expert Panel on effective ways of investing in health publishes opinion on supporting the mental health of the health workforce and other essential workers](#)

[COM\(2021\)627 – Regulation of the European Parliament and of the Council amending Regulation \(EU\) 2017/746 as regards transitional provisions for certain in vitro diagnostic medical devices and deferred application of requirements for in-house devices](#)

[Commission proposes a progressive roll-out of the new In Vitro Diagnostic Medical Devices Regulation](#)

[Questions and Answers on the progressive roll-out of the new In Vitro Diagnostic Medical Devices Regulation](#)

[Version 4.1 \(September 2021\) – Clinical Trials Regulation \(EU\)No 536/2014 Draft Questions & Answers](#)

[Full report – Hearing on European solidarity in public health emergencies \(16 September 2021\)](#)

[2021 EU Health Award – The Frequently Asked Question document has been updated](#)

[Minutes – 9th Plenary meeting of the Expert Panel \(22 September 2021\)](#)

[Calls for expression of interest; Representatives of Patients' Associations and Clinicians: Call for expressions of interest is open for the EMA Committee for Advanced Therapies; Civil Society representatives: Call for expressions of interest is open for the EMA Management Board; Civil Society representatives: Call for expressions of interest is open for the EMA Pharmacovigilance Risk Assessment Committee](#)

[SCCS – Request for a scientific advice on the safety of Homosalate as a UV-filter in cosmetic products](#)

[SCCS – Request for a scientific Opinion on Butylparaben](#)

[Minutes – Meeting of the Subgroup on Cancer \(8 July 2021\)](#)

[Consultation outcome – Cross-border healthcare: Evaluation of patients' rights](#)

[Flash report and presentations – Meeting of the Subgroup on Cancer \(23 September 2021\)](#)

Contactos



saude@vda.pt

Esta informação é de distribuição reservada, destinando-se exclusivamente aos clientes Vieira de Almeida, e não deve ser entendida como qualquer forma de publicidade, pelo que se encontra vedada a sua cópia ou circulação. A informação proporcionada e as opiniões expressas são de carácter geral, não substituindo o recurso a aconselhamento jurídico adequado para a resolução de casos concretos.